Findings: RCTSemaglutide vs Placebo for Alcohol Use Disorder in Adults, JAMA Psychiatry (2025) [PubMed abstract] Design: Randomized, placebo-controlled trial (N=48 | length = 9 weeks) in non-treatment-seeking adults with alcohol use disorder Treatment: Semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week) vs Placebo Primary outcome: Objective alcohol self-administration (at baseline and between Weeks 8 and 9) measured as follows: a standardized procedure was used to estimate voluntary alcohol consumption and ability to delay drinking
A phase 3 clinical trial evaluated the GLP-1 receptor agonist called Exenatide
Results vary, and its important not to think of semaglutide as a guaranteed amount of weight loss
Mild Reactions: The most common injection site reactions include transient redness (erythema), mild swelling, itching, and tenderness at the injection site
Price: Rs 359 / BoxGet Latest Price Product Brochure Product Details: We are leading Exporter and Manufacturer of Pharmaceutical Tablets Pharmaceutical Capsules Pharmaceutical Injection etc Zerofat A Capsule Approx
